Hepatitis D ultrasound: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatitis D}} | {{Hepatitis D}} | ||
{{CMG}}; {{AOEIC}} {{VK}} | {{CMG}}; {{AOEIC}} {{VK}}; {{JS}} {{JM}} | ||
==Overview== | ==Overview== | ||
Revision as of 00:14, 4 August 2014
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D ultrasound On the Web |
|
American Roentgen Ray Society Images of Hepatitis D ultrasound |
|
Risk calculators and risk factors for Hepatitis D ultrasound |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]; João André Alves Silva, M.D. [3] Jolanta Marszalek, M.D. [4]
Overview
The ultrasound may be used as a screening tool in patients with chronic hepatitis for the early detection of hepatic cirrhosis. Attending to the required concomitant existance of HDV and HBV, HBsAg carriers with cirrhosis should be echographically evaluated every 6 months.
Ultrasound
The following findings may be identified:[1]
- Coarse echogenicity
- Segmental hypertrophy with nodular appearance of liver
- Portal hypertension:
HBsAg carriers should have regular serial serum alpha-fetoprotein determinations, and ultrasound examinations (with 6 month intervals) for those above 40 years of age.[1]
Both these tests are recommended to be repeated regularly for all HBsAg carriers with cirrhosis.[1]
References
- ↑ 1.0 1.1 1.2 "Hepatitis D" (PDF).